# US 2025/0082582 A1 · Polymer-encapsulated drug particles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082582 A1
- Document ID: US20250082582A1
- Status: Published application
- Kind: A1
- Application number: 18/955,058
- Filed: 2024-11-21
- Published: 2025-03-13
- Earliest claimed: 2020-02-21
- Assignees: GIE Medical, Inc.
- Applicants: GIE Medical, Inc.
- Inventors: Lixiao Wang; Peter Barnett
- Web page: https://patentgrep.com/patent/US20250082582A1

## CPC

- A61K 9/4816: {Wall or shell material}
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61K 9/4833: {Encapsulating processes; Filling of capsules (mechanical aspects A61J3/07)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61L 29/085: {Macromolecular materials}
- A61M 25/10: Balloon catheters ({A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02;} inflatable balloons for placing stents or stent-grafts A61F2/958 {; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00})
- A61M 25/1029: {Production methods of the balloon members, e.g. blow-moulding, extruding, deposition or by wrapping a plurality of layers of balloon material around a mandril}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2300/606: Coatings
- A61L 2300/62: Encapsulated active agents, e.g. emulsified droplets
- A61L 2300/63: Crystals
- A61L 2300/802: Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
- A61M 2025/1031: {Surface processing of balloon members, e.g. coating or deposition; Mounting additional parts onto the balloon member's surface}
- A61M 2025/105: {having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes}
- A61M 2210/105: Oesophagus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Various embodiments disclosed relate to polymer-encapsulated drug particles and a drug-releasing coating including the same, as well as drug-coated balloon catheters for treating, preventing, or reducing the recurrence of strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes the polymer-encapsulated drug particles; or a drug-releasing coating including the polymer-encapsulated drug particles; or a therapeutic agent and a first and/or second additive; or a combination thereof.

## Claims

### Claim 1

A method of treating a digestive disease, the method comprising:
providing a balloon catheter into a target site in a body lumen, wherein the body lumen is an esophagus, colon, biliary tract, stomach, small intestine, duodenum, jejunum, ileum, rectum, or large intestine, wherein the target site is at, proximate to, proximal to, or distal to a site of the digestive disease, wherein the balloon catheter comprises
an elongated balloon, and
a coating layer overlying an exterior surface of the balloon, wherein the coating layer comprises one or more additives and an initial drug load of a therapeutic agent;
inflating the balloon at the target site to contact the coating layer with walls of the body lumen at the target site;
deflating the balloon; and
removing the balloon catheter from the target site;
wherein the digestive disease is Barrett's disease, eosinophilic esophagitis, Crohn's disease, ulcerative colitis, inflammatory bowel disease (IBD), or a combination thereof, and wherein the method alleviates or eliminates symptoms of the digestive disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein a surgical procedure is performed at the target site prior to the providing of the balloon catheter at the target site.

### Claim 3 (depends on 1)

The method of claim 1, wherein the surgical procedure comprises an incision, an electroincision, a laser incision, a stricturotomy, a resection, an atherectomy, a needle knife electroincision, an episiotomy, an endoscopic mucosal resection (EMR), an endoscopic sub-mucosal dissection (ESD), or a combination thereof.

### Claim 4 (depends on 2)

The method of claim 2, further comprising performing the surgical procedure.

### Claim 5 (depends on 1)

The method of claim 1, wherein the disease is Barrett's disease, eosinophilic esophagitis, or a combination thereof, and wherein the body lumen is an esophagus.

### Claim 6 (depends on 1)

The method of claim 1, wherein the disease is Crohn's disease ulcerative colitis, inflammatory bowel disease (IBD), or a combination thereof, wherein the body lumen is a colon, biliary tract, stomach, small intestine, duodenum, jejunum, ileum, rectum, or large intestine.

### Claim 7 (depends on 1)

The method of claim 1, wherein the coating layer is soaked or flushed with a solution comprising water or saline prior to the inflating.

### Claim 8 (depends on 1)

The method of claim 1, wherein the coating layer is soaked in a solution comprising water or saline prior to insertion of the balloon catheter into the body.

### Claim 9 (depends on 1)

The method of claim 1, further comprising flushing the body lumen before or during inflation with a solution comprising water or saline such that the coating layer is hydrated with the solution.

### Claim 10 (depends on 1)

The method of claim 1, wherein at the time of providing the balloon catheter at the target site, the target site is free of strictures or stenoses.

### Claim 11 (depends on 1)

The method of claim 1, wherein at the time of providing the balloon catheter at the target site, the target site comprises a stricture or stenosis.

### Claim 12 (depends on 1)

The method of claim 1, wherein the one or more additives in the coating layer comprise N-acetylglucosamine, N-octyl-D-gluconamide, N-nonanoyl-N-methylglycamine, N-octanoyl-N-methyl glutamine, C6-ceramide, dihydro-C6-ceramide, cerabroside, sphingomyelin, galaclocerebrosides, lactocerebrosides, N-acetyl-D-sphingosine, N-hexanoyl-D-sphingosine, N-octonoyl-D-sphingosine, N-lauroyl-D-sphingosine, N-palmitoyl-D-sphingosine, N-oleoyl-D-sphingosine, PEG caprylic/capric diglycerides, PEG8 caprylic/capric glycerides, PEG caprylate, PEG8 caprylate, PEG caprate, PEG caproate, glyceryl monocaprylate, glyceryl monocaprate, glyceryl monocaproate, monolaurin, monocaprin, monocaprylin, monomyristin, monopalmitolein, monoolein, creatine, creatinine, agmatine, citrulline, guanidine, sucralose, aspartame, hypoxanthine, theobromine, theophylline, adenine, uracil, uridine, guanine, thymine, thymidine, xanthine, xanthosine, xanthosine monophosphate, caffeine, allantoin, (2-hydroxyethyl)urea, N,N′-bis(hydroxymethyl)urea, pentaerythritol propoxylate, pentaerythritol propoxylate/ethoxylate, glycerol ethoxylate, glycerol propoxylate, trimethylolpropane ethoxylate, pentaerythritol, dipentaerythritol, crown ether, 18-crown-6, 15-crown-5, 12-crown-4, or combinations thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the one or more additives in the coating layer comprises pentaerythritol ethoxylate (15/4), pentaerythritol ethoxylate (3/4), or a combination thereof.

### Claim 14 (depends on 1)

The method of claim 1, wherein the therapeutic agent comprises paclitaxel, a paclitaxel analogue, docetaxel, a docetaxel analogue, taxol, a taxol analogue, rapamycin, a rapamycin analogue, sirolimus, a sirolimus analogue, everolimus, an everolimus analogue, tacrolimus, a tacrolimus analogue, mammalian target of rapamycin (mTOR) inhibitors, an mTOR inhibitor analogue, or a combination thereof.

### Claim 15 (depends on 1)

The method of claim 1, wherein the therapeutic agent comprises paclitaxel.

### Claim 16 (depends on 1)

The method of claim 1, further comprising providing a scope in the body lumen.

### Claim 17 (depends on 16)

The method of claim 16, wherein the balloon catheter is loaded into the scope, or wherein the balloon catheter and the scope are positioned side-by-side.

### Claim 18 (depends on 16)

The method of claim 16, wherein the inflation of the balloon to contact the coating layer with the walls of the body lumen is visualizable via the scope.

### Claim 19

A method of treating a digestive disease, the method comprising:
providing a balloon catheter into a target site in a body lumen, wherein the body lumen is an esophagus, wherein the target site is at, proximate to, proximal to, or distal to a site of the digestive disease, wherein the balloon catheter comprises
an elongated balloon, and
a coating layer overlying an exterior surface of the balloon, wherein the coating layer comprises one or more additives and an initial drug load of a therapeutic agent;
inflating the balloon at the target site to contact the coating layer with walls of the body lumen at the target site;
deflating the balloon; and
removing the balloon catheter from the target site;
wherein a surgical procedure is performed at the target site prior to the providing of the balloon catheter at the target site, wherein the surgical procedure comprises an incision, an electroincision, a laser incision, a stricturotomy, a resection, an atherectomy, a needle knife electroincision, an episiotomy, an endoscopic mucosal resection (EMR), an endoscopic sub-mucosal dissection (ESD), or a combination thereof; and
wherein the digestive disease is Barrett's disease, eosinophilic esophagitis, or a combination thereof, and wherein the method alleviates or eliminates symptoms of the digestive disease.

### Claim 20

A method of treating a digestive disease, the method comprising:
providing a balloon catheter into a target site in a body lumen, wherein the body lumen is a colon, biliary tract, stomach, small intestine, duodenum, jejunum, ileum, rectum, or large intestine, wherein the target site is at, proximate to, proximal to, or distal to a site of the digestive disease, wherein the balloon catheter comprises
an elongated balloon, and
a coating layer overlying an exterior surface of the balloon, wherein the coating layer comprises one or more additives and an initial drug load of a therapeutic agent;
inflating the balloon at the target site to contact the coating layer with walls of the body lumen at the target site;
deflating the balloon; and
removing the balloon catheter from the target site;
wherein a surgical procedure is performed at the target site prior to the providing of the balloon catheter at the target site, wherein the surgical procedure comprises an incision, an electroincision, a laser incision, a stricturotomy, a resection, an atherectomy, a needle knife electroincision, an episiotomy, an endoscopic mucosal resection (EMR), an endoscopic sub-mucosal dissection (ESD), or a combination thereof; and
wherein the digestive disease is Crohn's disease, ulcerative colitis, Inflammatory bowel disease (IBD), or a combination thereof, and wherein the method alleviates or eliminates symptoms of the digestive disease.
